MiMedx Group, Inc. (MDXG)
| Market Cap | 911.68M |
| Revenue (ttm) | 340.46M |
| Net Income (ttm) | 80.67M |
| Shares Out | 146.81M |
| EPS (ttm) | 0.53 |
| PE Ratio | 11.73 |
| Forward PE | 23.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 377,828 |
| Open | 6.12 |
| Previous Close | 6.15 |
| Day's Range | 6.06 - 6.33 |
| 52-Week Range | 5.57 - 9.27 |
| Beta | 1.98 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+93.24%) |
| Earnings Date | Oct 28, 2024 |
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for MDXG stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 93.24% from the latest price.
News
EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"
10 Former MiMedx Employees In Non-Compete Suit Fight Back Against MiMedx Schemes to "Bilk Medicare" and "Incentivize Fraud" in Counterclaims Filed by Mintz Attorneys MARIETTA, Ga. , Sept. 11, 2024 /PR...
THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'
Ex-MiMedx Employee Jake Heikkinen Files Counterclaims Alleging Schemes 'To Bilk Medicare' and 'Incentivize and Pressure Healthcare Providers' per Mintz Attorneys MARIETTA, Ga. , Sept. 4, 2024 /PRNewsw...
DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT
Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for "Predatory Sales Practices" and "Incentivized Fraud" per Mintz Attorneys MARIETTA, Ga. , Aug. 26, 2024 /PRNewswire/ -- One of 10 defendants wh...
MiMedx Group, Inc. (MDXG) Q2 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Ri...
MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix
Limited market release marks first xenograft addition to Company's portfolio of leading Wound and Surgical products Limited market release marks first xenograft addition to Company's portfolio of lead...
MIMEDX Announces Second Quarter 2024 Operating and Financial Results
Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12 , Respectively Second Quarter Adjusted EBITDA wa...
MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
Study adds to the Company's growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process
MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has...
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following in...
MiMedx Group, Inc. (MDXG) Q1 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head of Investor Relations Joe Capper - Chief Executive Officer Doug...
MIMEDX Announces First Quarter 2024 Operating and Financial Results
Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host...
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first qu...
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating wounds Exclusive agreement...
MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript
MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference
MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44th Annual Healt...
MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28
MARIETTA, Ga., Feb. 12, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth qu...
MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing
New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic Priorities New Credit Facilities Provide Substantial Interest Savings and ...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MiMedx Group, Inc...
The Law Offices of Frank R. Cruz Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) on behalf of investors concerning the Company...
MiMedx reports US FDA warning letter for Axiofill, shares drop
MiMedx Group said on Friday it had received a warning letter from the U.S. Food and Drug Administration related to the classification of its placental-derived tissue product Axiofill, and its shares f...
MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook
Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety Request for Designation for AXIOFILL Submitted to FDA and Currently Under Review Reiterates Expectations for 2023 Net S...
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
MARIETTA, Ga., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that its outstanding 95,000 shares of Series B Convertible Preferred Stoc...
MIMEDX to Highlight Published Data at SAWC Fall
MARIETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it will sponsor an Innovation Theater lunch symposium at the Symposium on...
MiMedx Group, Inc. (MDXG) Q3 2023 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2023 Earnings Call October 30, 2023 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph H. Capper - Chief Executive Officer Doug Rice...